Krakow, Poland – November 23, 2020 – Ryvu Therapeutics (WSE:RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced the appointment of Kamil Sitarz, Ph.D., MBA, to the Management Board of the Company.
At the same time Dr Sitarz, who previously served as Head of R&D Operations, was now promoted to the Chief Operating Officer position. He will hold an executive responsibility for design, implementation, and co-ordination of day-to-day business operations, as well as financial and performance management at Ryvu Therapeutics. Moreover, he will be in charge of establishing and implementing corporate policies, procedures and processes, as well as management of administrative and operational functions at the Company.
I am very happy to see Kamil take over the position of Chief Operating Officer and join us on the Management Board. I have observed his professional development from the Senior Scientist position when he joined us in 2013, through subsequent mid- and senior managerial roles until today. He is an exceptionally creative, hard-working, and reliable person with a diverse professional background which I am sure will make him a great addition to the Ryvu’s Management Board – comments Pawel Przewiezlikowski, Chief Executive Officer.
Kamil Sitarz joined Ryvu Therapeutics in 2013 as a Senior Scientist and Biology Leader. Subsequently, he was promoted to the position of Principal Investigator/Project Manager, and later on to Director of R&D Biology Department. After the corporate split in 2019, Dr Sitarz became the Head of R&D Operations, and in November 2020, he was promoted to the Chief Operating Officer position, along with his appointment to the Management Board of the Company.
Dr Sitarz holds an M.Sc. degree in Biophysics from Jagiellonian University (Krakow, Poland) and a Ph.D. degree in Human/Medical Genetics from Newcastle University (Newcastle upon Tyne, UK). He has also graduated from the joint Executive MBA program at Cracow School of Business CUE, EM Normandie Business School, and AESE Business School. He is the co-author of a dozen of scientific publications in peer-reviewed journals.